Institutional shares held 72.2 Million
187K calls
225K puts
Total value of holdings $421M
$1.09M calls
$1.31M puts
Market Cap $199M
34,072,200 Shares Out.
Institutional ownership 211.89%
# of Institutions 156


Latest Institutional Activity in EYPT

Top Purchases

Q1 2025
Gamma Investing LLC Shares Held: 10.2K ($59.8K)
Q1 2025
Massmutual Trust CO Fsb Shares Held: 345 ($2.01K)
Q1 2025
Versant Capital Management, Inc Shares Held: 741 ($4.32K)
Q1 2025
Parallel Advisors, LLC Shares Held: 121 ($705)
Q1 2025
Rothschild Investment LLC Shares Held: 120 ($700)

Top Sells

Q1 2025
Rhumbline Advisers Shares Held: 86.7K ($506K)
Q4 2024
Morgan Stanley Shares Held: 745K ($4.35M)
Q4 2024
T. Rowe Price Investment Management, Inc. Shares Held: 207K ($1.21M)
Q4 2024
Deutsche Bank Ag\ Shares Held: 213K ($1.24M)
Q4 2024
Essex Woodlands Management, Inc. Shares Held: 1.17M ($6.82M)

About EYPT

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.


Insider Transactions at EYPT

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.74M Shares
From 12 Insiders
Open market or private purchase 1.46M shares
Exercise of conversion of derivative security 280K shares
Sell / Disposition
94.8K Shares
From 4 Insiders
Payment of exercise price or tax liability 39.9K shares
Other acquisition or disposition 20K shares
Open market or private sale 34.9K shares

Track Institutional and Insider Activities on EYPT

Follow EyePoint Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EYPT shares.

Notify only if

Insider Trading

Get notified when an Eye Point Pharmaceuticals, Inc. insider buys or sells EYPT shares.

Notify only if

News

Receive news related to EyePoint Pharmaceuticals, Inc.

Track Activities on EYPT